anti-Δ5 integrin blocking antibody

The term anti-Δ5 integrin blocking antibody appears to be a typographical variation of an anti-α5 (alpha 5) integrin blocking antibody. Integrin α5 (ITGA5) typically dimerizes with the β1 subunit to form the α5β1 integrin, also known as the fibronectin receptor (VLA-5). This integrin plays a critical role in cell adhesion, migration, and signaling, particularly in the context of tumor angiogenesis and metastasis. Blocking antibodies targeting this integrin are designed to inhibit the interaction between α5β1 and its ligand, fibronectin, thereby disrupting the formation of new blood vessels that support tumor growth and preventing the survival and migration of malignant cells. While several candidates, such as the chimeric monoclonal antibody volociximab (M200) and the humanized antibody PF-04605412, have entered clinical trials for various solid tumors, none have yet achieved widespread regulatory approval for oncology indications.